Skin Cancer Life Insurance Underwriting Guide

Can You Qualify for Preferred Life Insurance Rates After Skin Cancer?

A history of skin cancer does not automatically mean an applicant will receive a rated life insurance offer — or even that the applicant cannot qualify for favorable rates. Skin cancer is one of the clearest examples of why simply answering yes to a cancer-history question tells an underwriter very little.

There is an enormous difference between a small basal cell carcinoma removed during a routine dermatology visit and an invasive melanoma that has spread to regional lymph nodes. For life insurance underwriting, the important questions are the exact cancer type, depth or stage, completeness of treatment, ulceration, lymph-node involvement, recurrence history, surveillance, and time since treatment.

Most common skin cancers are basal cell carcinoma and squamous cell carcinoma. These usually carry much less mortality significance than melanoma. That creates a practical underwriting sweet spot: an applicant may have a true history of cancer yet still represent a very favorable mortality risk when the lesion was localized, completely treated, and followed appropriately.

Editorial principle. Skin cancer is not an underwriting diagnosis. The phrase "skin cancer" spans conditions with dramatically different mortality implications. The advisor should identify the exact pathology before assuming the case is impaired.

Basal Cell Carcinoma: Often the Most Favorable History

Basal cell carcinoma (BCC) is the most common skin cancer. It generally grows slowly and very rarely metastasizes. Although neglected lesions can become locally destructive, a small localized BCC that has been completely removed is usually a very different life-insurance risk from melanoma.

Underwriters may consider the number of lesions, recurrence pattern, location, pathology, immune status, completeness of excision, and dermatology follow-up. Depending on the carrier and the applicant's overall health, a routine treated BCC may have little effect on the final offer and can sometimes remain compatible with Standard or better consideration.

Squamous Cell Carcinoma: Usually Favorable, but Look More Closely

Squamous cell carcinoma (SCC) is another common non-melanoma skin cancer. Most cutaneous SCCs are localized and successfully treated, but SCC has more metastatic potential than BCC. Underwriters may pay closer attention to tumor size, depth, location, recurrence, differentiation, immune suppression, margins, and lymph-node findings.

An uncomplicated localized SCC that has been completely excised may still be a favorable life-insurance history. Aggressive, recurrent, deeply invasive, or node-positive SCC requires a more conservative review.

Melanoma Changes the Underwriting Discussion

Melanoma arises from melanocytes and is less common than BCC or SCC, but it has a substantially greater ability to spread to lymph nodes and distant organs. For an underwriter, the statement "I had melanoma" is only the beginning of the analysis.

The pathology report becomes central. Two measurements commonly encountered are Clark Level and Breslow Thickness. Clark describes the anatomical layer reached by the melanoma. Breslow measures the actual vertical thickness in millimeters. Modern staging places much greater emphasis on Breslow thickness, ulceration, nodal status, and metastatic spread than on Clark Level alone.

Clark Level Reference

Clark I: Melanoma confined to the epidermis — melanoma in situ. Most favorable melanoma category; complete excision and recurrence history remain important.
Clark II: Tumor invades the papillary dermis. Early invasion; assess Breslow thickness, ulceration, margins and elapsed time.
Clark III: Tumor fills the papillary dermis and reaches the interface with the reticular dermis. More meaningful invasion; Breslow and full staging become increasingly important.
Clark IV: Tumor invades the reticular dermis. Greater depth and mortality concern; rating, flat extra or postponement may be more likely depending on complete staging.
Clark V: Tumor reaches subcutaneous tissue beneath the dermis. Deep invasion; substantially greater concern, especially if ulcerated, node-positive or metastatic.

Clark Level is still useful, especially in older pathology, but it is not the primary modern gauge when Breslow thickness and current staging are available. Public reinsurance underwriting literature notes that Breslow depth is preferred over Clark level when the two conflict and that Clark has limited value in thicker lesions.

Breslow Thickness: The Modern Measurement Advisors Should Find

Breslow Thickness measures the vertical depth of an invasive melanoma in millimeters. It is measured from the upper reference point of the lesion to the deepest malignant melanoma cell. Because it is an actual measurement rather than an anatomical-layer category, it provides a more precise description of tumor depth.

The current AJCC framework divides primary melanoma thickness into practical T categories and then considers ulceration. This is the most useful modern reference for advisors; it should not be confused with older historical Breslow groupings sometimes seen in legacy records.

T1a (<0.8 mm, no ulceration): Very thin invasive melanoma; often the most favorable invasive group when completely treated and node-negative.
T1b (<0.8 mm ulcerated, or 0.8–1.0 mm either status): Still thin, but ulceration and the 0.8 mm threshold increase staging significance.
T2a/T2b (>1.0–2.0 mm; a = no ulceration, b = ulcerated): Intermediate thickness; underwriting becomes more conservative and disease-free interval more important.
T3a/T3b (>2.0–4.0 mm; a = no ulceration, b = ulcerated): Thicker melanoma with materially greater concern; flat extras, ratings or postponement may be considered depending on complete history.
T4a/T4b (>4.0 mm; a = no ulceration, b = ulcerated): Very thick primary melanoma; high concern, especially with ulceration or nodal/metastatic involvement.

Older references may show historical Breslow groupings such as ≤0.75 mm, 0.76–1.5 mm, 1.51–4 mm, and ≥4 mm. Those groupings can help interpret older records, but current staging uses the AJCC thresholds above. For life underwriting, thickness never stands alone: ulceration, lymph nodes, metastasis, treatment, recurrence, and elapsed disease-free time can change the outcome materially.

Advisor rule. Get the pathology report before you shop the case. A note saying "melanoma removed five years ago" is much less useful than a pathology summary such as "Breslow 0.6 mm, no ulceration, clear margins, node-negative, no recurrence." The pathology turns a vague cancer history into an underwritable risk profile.

Melanoma In Situ and Thin Melanoma

Melanoma in situ means malignant melanocytes remain confined to the epidermis and have not invaded the dermis. It corresponds to Clark Level I. When completely excised with clear margins and without recurrence, it may represent a surprisingly favorable melanoma history. Carrier treatment varies, and preferred-class rules are company-specific.

Once melanoma becomes invasive, the Breslow measurement becomes crucial. A thin, non-ulcerated, node-negative melanoma can be dramatically different from a thicker ulcerated lesion even though both are labeled melanoma. Underwriters usually want the exact Breslow depth, ulceration status, margins, sentinel-node findings if performed, stage, treatment date, and surveillance history.

Ulceration and Lymph Nodes Can Change the Case

Ulceration is a microscopic breakdown of the epidermal surface overlying the melanoma. It is an adverse prognostic feature and is incorporated directly into AJCC T categorization. Two melanomas with similar thickness can therefore have different staging significance when one is ulcerated and the other is not.

Lymph-node involvement is another major dividing line. A melanoma confined to the primary site is fundamentally different from one that has reached regional nodes. A sentinel lymph-node biopsy, when clinically indicated, helps determine whether microscopic spread has occurred. A negative result can be favorable evidence; a positive result changes staging and usually produces much more conservative underwriting.

Practical Skin Cancer Underwriting Ladder

Small, completely removed basal cell carcinoma: Frequently very favorable; Standard or better may be possible depending on carrier and overall risk.
Localized, completely removed cutaneous squamous cell carcinoma: Often favorable; aggressive features or immune suppression can change the result.
Melanoma in situ / Clark I: Potentially favorable after complete excision and appropriate follow-up.
Very thin invasive melanoma, favorable pathology: Often insurable; carrier may consider Standard, a temporary flat extra, rating, or waiting period depending on details.
Intermediate-thickness melanoma: Greater chance of temporary flat extra, table rating or postponement.
Thick or ulcerated melanoma: More significant mortality concern; underwriting becomes substantially more conservative.
Positive regional lymph nodes: Major adverse factor; often longer postponement and/or substantial rating if later considered.
Metastatic or recurrent melanoma: Frequently not currently insurable in traditional individual life underwriting until a sufficiently favorable subsequent history develops.

These are directional industry-style observations, not promises or proprietary carrier/reinsurer rating tables. Complete underwriting manuals from major reinsurers are generally client-restricted. Public reinsurance underwriting material supports the importance of Breslow thickness, ulceration, mitotic activity, nodal involvement, and the reduced modern role of Clark Level.

Time Since Last Treatment: When Standard or a Temporary Flat Extra May Be Possible

Cancer underwriting is partly an assessment of recurrence risk. A longer disease-free interval can reduce uncertainty, but the amount of time required depends on the exact pathology and stage. Public reinsurance medical literature emphasizes stage, Breslow thickness, ulceration, nodal status, recurrence, and ongoing surveillance, and notes that melanoma recurrence risk can persist well beyond five years, particularly with thicker or higher-risk tumors.

Complete rating manuals of major reinsurers are generally proprietary or client-restricted. The elapsed-time examples below are tied to publicly available field-underwriting guides, while the medical underwriting rationale is separately tied to public reinsurance and government medical sources, so a carrier timetable is not attributed to a reinsurer that has not published it.

Basal cell carcinoma, fully removed: Best-case published guidance allows Standard immediately on removal; Preferred may be possible when pathology and follow-up are favorable.
Cutaneous SCC, favorable localized case, after complete removal: Best-case published guidance can be Standard; final treatment depends on size, depth, differentiation, location, immune status, margins, recurrence, and nodal findings.
Cutaneous SCC, less favorable localized case: Individual underwriting; public guidance does not support one universal waiting-period rule for every SCC, so elapsed time should not be inferred without pathology.
Cutaneous SCC, non-best cases: Published field-underwriting examples include temporary flat extras of roughly $7.50/$1,000 for 4 years to $10/$1,000 for 5 years in selected non-best cases.
Cutaneous SCC, favorable longer-term follow-up: Potential Standard consideration depends on pathology and follow-up rather than a single universal year threshold.
Melanoma in situ / Stage 0, after complete treatment: Published guidance shows favorable melanoma in situ may qualify for Standard and, in selected guidance, Preferred consideration.
Favorable localized invasive melanoma, immediately after excision / early years: Published guidance includes temporary extras of about $5–$7 per $1,000 for 3 years in many favorable cases, with other examples varying by thickness, location and ulceration.
Favorable melanoma after the initial extra period: The temporary-extra period can end as the case matures, but Standard timing is carrier-specific; one published field guide indicates Standard Plus may be possible 10 years after first qualifying for Standard.
Deeper invasive melanoma, first several years after treatment: Published guidance indicates deeper lesions may require a minimum 2–5 year decline/postponement period following treatment before reconsideration.
Deeper or otherwise adverse melanoma, after postponement: Subsequent consideration depends on Breslow thickness, ulceration, nodal status, recurrence, treatment, and disease-free interval; no single public schedule should be treated as universal.
Node-positive melanoma: A longer disease-free interval is generally required; timing and rating are individualized and may remain substandard even after substantial disease-free follow-up.
Advanced melanoma: Extended follow-up required; public reinsurance literature emphasizes recurrence risk, stage, nodal status, and long-term follow-up rather than a universal Standard timetable.
Metastatic melanoma: Generally not a routine Standard/flat-extra case; active or recent metastatic disease is commonly uninsurable until a substantially more favorable long-term history develops, if reconsideration is available at all.

Advisor interpretation: the most defensible "Standard or small temporary flat extra" opportunities in the cited public guidance are fully removed BCC, favorable localized SCC, melanoma in situ, and Stage 1 melanoma. Stage 2 and higher disease should not be marketed as an easy Standard trajectory because the published examples remain postponed or materially rated for much longer periods.

Do not shop the clock without the pathology. Elapsed time is never a substitute for Breslow thickness, ulceration, nodal status, margins, recurrence, treatment, and surveillance. The same number of years since treatment can produce very different offers when the underlying stage or pathology differs.

The Advisor's Skin Cancer Checklist

Exact diagnosis: basal cell, squamous cell, melanoma in situ, or invasive melanoma
Date of diagnosis, date of last treatment, and length of disease-free interval
Original pathology report
Breslow Thickness in millimeters
Clark Level, if reported
Ulceration status
Surgical margins
Sentinel-node or other lymph-node results
Stage and any metastatic disease
Treatment performed
Recurrence history
Most recent dermatology/oncology follow-up

Bottom Line for Advisors

Skin cancer is not an underwriting diagnosis. Basal cell carcinoma, routine cutaneous squamous cell carcinoma, melanoma in situ, thin invasive melanoma, and metastatic melanoma occupy dramatically different mortality categories.

The most productive underwriting conversation begins with the pathology report. The advisor who can provide Breslow depth, ulceration, margins, nodal status, treatment, and recurrence history gives the underwriter the information needed to distinguish an ordinary favorable history from a significant cancer impairment.

Sources

John Hancock Life Insurance Company (U.S.A.), Field Underwriting Guide, "Cancer: Skin Malignant"
iA Financial Group (Industrial Alliance), Field Underwriting Guide for Representatives — Skin cancer (malignant melanoma and squamous cell carcinoma)
Munich Re Life US, Bradley Heltemes, MD, "Malignant Melanoma" — Underwriting of Melanoma for Life and DI Coverage
Gen Re, Mary Enslin, "Melanoma Monday — an Update on Skin Cancer Claims"
National Cancer Institute, Melanoma Treatment (PDQ), AJCC 8th Edition staging information
National Cancer Institute / SEER, Melanoma Staging and Summary Stage resources
Swiss Re, Life Guide product page (evidence-based Life & Health underwriting resource)

This article is educational only and is not medical, legal, tax or insurance advice. It is not an offer, quote or promise of eligibility or rate class. Underwriting guidelines, reinsurance practices, products and pricing vary by insurer, jurisdiction, age and individual facts and can change without notice. The issuing carrier makes the final underwriting decision. Applicants should answer all questions completely and truthfully and make medical decisions with licensed healthcare professionals.

Skin Cancer and Life Insurance Underwriting